Senate Finance Report Might Shed Light on Insulin Manufacturers’ 340B Contract Pharmacy Actions

U.S. insulin manufacturer and pharmacy benefit manager (PBM) business practices “have created a vicious cycle of price increases that have sent costs for patients and taxpayers through the roof,” U.S. Senate Finance Committee leaders Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.) said last week upon releasing the results of their two-year-long investigation “into the skyrocketing price of insulin.”